Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
NCT04491721
·
clinicaltrials.gov ↗
ENROLLING_BY_INVITATION
Status
407
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma
Sponsor
Chinese Academy of Medical Sciences